We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Stock Moves -0.28%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Viatris (VTRS - Free Report) closed at $10.67, marking a -0.28% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.34%.
Coming into today, shares of the generic drugmaker had gained 9.07% in the past month. In that same time, the Medical sector gained 8.23%, while the S&P 500 gained 5.03%.
Viatris will be looking to display strength as it nears its next earnings release, which is expected to be May 9, 2022. The company is expected to report EPS of $0.84, down 8.7% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.28 billion, down 3.37% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.46 per share and revenue of $17.36 billion. These totals would mark changes of -6.49% and -2.92%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Viatris. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.53% lower. Viatris is holding a Zacks Rank of #5 (Strong Sell) right now.
Valuation is also important, so investors should note that Viatris has a Forward P/E ratio of 3.09 right now. Its industry sports an average Forward P/E of 25.39, so we one might conclude that Viatris is trading at a discount comparatively.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 213, which puts it in the bottom 16% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris (VTRS) Stock Moves -0.28%: What You Should Know
In the latest trading session, Viatris (VTRS - Free Report) closed at $10.67, marking a -0.28% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.34%.
Coming into today, shares of the generic drugmaker had gained 9.07% in the past month. In that same time, the Medical sector gained 8.23%, while the S&P 500 gained 5.03%.
Viatris will be looking to display strength as it nears its next earnings release, which is expected to be May 9, 2022. The company is expected to report EPS of $0.84, down 8.7% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.28 billion, down 3.37% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.46 per share and revenue of $17.36 billion. These totals would mark changes of -6.49% and -2.92%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Viatris. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.53% lower. Viatris is holding a Zacks Rank of #5 (Strong Sell) right now.
Valuation is also important, so investors should note that Viatris has a Forward P/E ratio of 3.09 right now. Its industry sports an average Forward P/E of 25.39, so we one might conclude that Viatris is trading at a discount comparatively.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 213, which puts it in the bottom 16% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.